Combination Osteogenic Therapy in Established Osteoporosis
Status:
Completed
Trial end date:
2003-10-01
Target enrollment:
Participant gender:
Summary
This study is designed to determine if combining parathyroid (PTH 1-34) with fluoride (MFPSR)
therapy in a cyclic treatment regimen will: (1) produce a greater increase in bone density of
the spine than would be produced by either treatment alone; (2) prevent the resistance (i.e.,
decreased bone formation and no further increase in bone density) that is observed within
18-24 months of PTH therapy; (3) eliminate the calcium deficiency and osteomalacia that can
occur with fluoride; (4) prevent excessive bone fluoride content; and (5) result in an
increase in bone density which is maintained after treatment is discontinued.
Phase:
Phase 2
Details
Lead Sponsor:
US Department of Veterans Affairs VA Office of Research and Development